: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Vaccines

Free Subscription

Articles published in J Infect Dis
Retrieve available abstracts of 421 articles:
HTML format

Single Articles

April 2024

Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
J Infect Dis. 2024 Apr 18:jiae186. doi: 10.1093.
PubMed

NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al
Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093.
PubMed Abstract available

COHEN MS, Marrazzo J
What if We Had a Vaccine that Prevents Neisseria gonorrhoeae.
J Infect Dis. 2024 Apr 17:jiae160. doi: 10.1093.
PubMed

WALSH EE, Falsey AR, Zareba AM, Jiang Q, et al
Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
J Infect Dis. 2024 Apr 12:jiae185. doi: 10.1093.
PubMed Abstract available

UZZELL CB, Abraham D, Rigby J, Troman CM, et al
Environmental Surveillance for Salmonella Typhi and its Association With Typhoid Fever Incidence in India and Malawi.
J Infect Dis. 2024;229:979-987.
PubMed Abstract available

SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
J Infect Dis. 2024;229:1077-1087.
PubMed Abstract available

THOMPSON KM, Kalkowska DA, Routh JA, Brenner IR, et al
Modeling Poliovirus Transmission and Responses in New York State.
J Infect Dis. 2024;229:1097-1106.
PubMed Abstract available

SABAWOON W, Seino S, Pason BM, Momin NWS, et al
Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
J Infect Dis. 2024 Apr 10:jiae129. doi: 10.1093.
PubMed Abstract available

CHEN MH, Perelygina L, Hao L, Beard RS, et al
Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins.
J Infect Dis. 2024 Apr 9:jiae182. doi: 10.1093.
PubMed Abstract available

PONZILACQUA-SILVA B, Dadelahi AS, Abushahba MFN, Moley CR, et al
Vaccine Elicited Antibodies Restrict Glucose Availability to Control Brucella Infection.
J Infect Dis. 2024 Apr 8:jiae172. doi: 10.1093.
PubMed Abstract available

BARTSCH SM, O'Shea KJ, Weatherwax C, Strych U, et al
What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective?
J Infect Dis. 2024 Apr 6:jiae179. doi: 10.1093.
PubMed Abstract available

TAIT D, Diacon A, Borges AH, van Brakel E, et al
Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
PubMed Abstract available

March 2024

KAO CM, Rostad CA, Nolan LE, Peters E, et al
A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
PubMed Abstract available

KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al
Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093.
PubMed Abstract available

FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al
Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
PubMed Abstract available

PRUNAS O, Shioda K, Toscano CM, Bastias M, et al
Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.
J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093.
PubMed Abstract available

KING LM, Andrejko KL, Kabbani S, Tartof SY, et al
Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093.
PubMed Abstract available

PRASAD AN, Geisbert TW
A glass-half-full perspective on negative data in Ebolavirus vaccine studies.
J Infect Dis. 2024 Mar 15:jiae109. doi: 10.1093.
PubMed

VAN TOL S, Fletcher P, Feldmann F, Mukesh RK, et al
A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
J Infect Dis. 2024 Mar 15:jiae056. doi: 10.1093.
PubMed Abstract available

ROSSLER A, Knabl L, Netzl A, Bante D, et al
Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
J Infect Dis. 2024;229:644-647.
PubMed Abstract available

GRUNER E, Grossegesse M, Stern D, Ober V, et al
Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093.
PubMed Abstract available

FIERRO C, Brune D, Shaw M, Schwartz H, et al
Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial.
J Infect Dis. 2024 Mar 13:jiae114. doi: 10.1093.
PubMed Abstract available

MUNK C, Reinholdt K, Kjaer AK, Hemmingsen CH, et al
Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.
J Infect Dis. 2024 Mar 12:jiae068. doi: 10.1093.
PubMed Abstract available

SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al
Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review.
J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093.
PubMed Abstract available

LIM WW, Shuo F, Wong SS, Sullivan SG, et al
Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093.
PubMed Abstract available

COLON W, Oriol Mathieu V, Hural J, Hattingh L, et al
HIV Diagnostics and Vaccines: It Takes Two to Tango.
J Infect Dis. 2024 Mar 7:jiae113. doi: 10.1093.
PubMed Abstract available

WESTERCAMP N, Osei-Tutu L, Schuerman L, Kariuki SK, et al
Could less be more? Accounting for fractional-dose regimens and different number of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
J Infect Dis. 2024 Mar 4:jiae075. doi: 10.1093.
PubMed Abstract available

CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093.
PubMed Abstract available

February 2024

CAO Y, Hayashi CTH, Kumar N
A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei.
J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093.
PubMed Abstract available

WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al
A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diverse Klebsiella pneumoniae isolates.
J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093.
PubMed Abstract available

DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al
Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Chlamydia-Infected Women with Different Chlamydia Outcomes.
J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093.
PubMed Abstract available

SHAW CA, Essink B, Harper C, Mithani R, et al
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase I Clinical Trial in Healthy Older Adults.
J Infect Dis. 2024 Feb 22:jiae081. doi: 10.1093.
PubMed Abstract available

CHALKIAS S, McGhee N, Whatley JL, Essink B, et al
Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093.
PubMed Abstract available

FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Shriver M, et al
Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge.
J Infect Dis. 2024 Feb 8:jiae062. doi: 10.1093.
PubMed Abstract available

BURKE RM, Payne DC, McNeal M, Conrey SC, et al
Correlates of Rotavirus Vaccine Shedding and Seroconversion in a U.S. Cohort of Healthy Infants.
J Infect Dis. 2024 Feb 8:jiae055. doi: 10.1093.
PubMed Abstract available

HU X, Karthigeyan KP, Herbek S, Valencia SM, et al
Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
J Infect Dis. 2024 Feb 7:jiad593. doi: 10.1093.
PubMed Abstract available

January 2024

SHAW CA, Mithani R, Kapoor A, Dhar R, et al
Safety, Tolerability and Immunogenicity of a mRNA-based RSV Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
J Infect Dis. 2024 Jan 31:jiae035. doi: 10.1093.
PubMed Abstract available

MCCARTHY KN, Hone S, McLoughlin RM, Mills KHG, et al
IL-17 and IFN-gamma-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines.
J Infect Dis. 2024 Jan 30:jiae034. doi: 10.1093.
PubMed Abstract available

LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093.
PubMed

CARROLL TD, Wong T, Morris MK, Di Germanio C, et al
Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.
J Infect Dis. 2024 Jan 12:jiad568. doi: 10.1093.
PubMed Abstract available

HARRER CE, Mayer L, Fathi A, Lassen S, et al
Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans.
J Infect Dis. 2024 Jan 9:jiad612. doi: 10.1093.
PubMed Abstract available

HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al
Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
PubMed Abstract available

December 2023

SAJKOV D, Woodman R, Honda-Okubo Y, Barbara J, et al
A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.
J Infect Dis. 2023 Dec 29:jiad589. doi: 10.1093.
PubMed Abstract available

ZHANG Y, Zhou Y, Chen J, Wu J, et al
Vaccination Shapes Within-Host SARS-CoV-2 Diversity of Omicron BA.2.2 Breakthrough Infection.
J Infect Dis. 2023 Dec 27:jiad572. doi: 10.1093.
PubMed Abstract available

WIDAGDO W, Bastian AR, Jastorff AM, Scheys I, et al
Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-dose Influenza Vaccine in Adults 65 Years and Older: a Noninferiority Trial.
J Infect Dis. 2023 Dec 22:jiad594. doi: 10.1093.
PubMed Abstract available

HERMIDA N, Ferguson M, Leroux-Roels I, Pagnussat S, et al
Safety and Immunogenicity of Respiratory Syncytial Virus Pre-fusion Maternal Vaccine Co-administered with Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
J Infect Dis. 2023 Dec 22:jiad560. doi: 10.1093.
PubMed Abstract available

YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al
Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
J Infect Dis. 2023;228:1652-1661.
PubMed Abstract available

PENETRA SLS, Santos HFP, Resende PC, Bastos LS, et al
SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
J Infect Dis. 2023;228:1680-1689.
PubMed Abstract available

F SCHWARZ T, Hwang SJ, Ylisastigui P, Liu CS, et al
Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
J Infect Dis. 2023 Dec 14:jiad546. doi: 10.1093.
PubMed Abstract available

HUH K, Kang M, Kim YE, Choi Y, et al
Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
J Infect Dis. 2023 Dec 14:jiad501. doi: 10.1093.
PubMed Abstract available

ELLINGSON MK, Weinberger DM, van der Linden M, Perniciaro S, et al
Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany.
J Infect Dis. 2023 Dec 6:jiad538. doi: 10.1093.
PubMed Abstract available

TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093.
PubMed Abstract available

November 2023

TUTTLE DJ, Castanha PMS, Nasser A, Wilkins MS, et al
SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1.
J Infect Dis. 2023 Nov 30:jiad544. doi: 10.1093.
PubMed Abstract available

FELL DB, Russell M, Fung SG, Swayze S, et al
Effectiveness of maternal influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada.
J Infect Dis. 2023 Nov 29:jiad539. doi: 10.1093.
PubMed Abstract available

LEE K, Williams KV, Englund JA, Sullivan SG, et al
The potential benefits of delaying seasonal influenza vaccine selections for the Northern Hemisphere: a retrospective modeling study in the United States.
J Infect Dis. 2023 Nov 29:jiad541. doi: 10.1093.
PubMed Abstract available

KARABA AH, Morgenlander WR, Johnston TS, Hage C, et al
Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.
J Infect Dis. 2023 Nov 29:jiad534. doi: 10.1093.
PubMed Abstract available

CISZEWSKI J, Taniuchi M, Lee B, Colgate ER, et al
Differences in Rotavirus Shedding and Duration by Infant Oral Rotavirus Vaccination Status in Dhaka, Bangladesh 2011 - 2014.
J Infect Dis. 2023 Nov 29:jiad502. doi: 10.1093.
PubMed Abstract available

GIULIANO AR, Palefsky JM, Goldstone SE, Dubin B, et al
High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
J Infect Dis. 2023 Nov 28:jiad485. doi: 10.1093.
PubMed Abstract available

PICHICHERO ME, Xu L, Gonzalez E, Pham M, et al
Variability of Vaccine Responsiveness in Young Children.
J Infect Dis. 2023 Nov 22:jiad524. doi: 10.1093.
PubMed Abstract available

LU X, Liu F, Tzeng WP, York IA, et al
Antibody-mediated Suppression Regulates the Humoral Immune Response to Influenza Vaccination in Humans.
J Infect Dis. 2023 Nov 20:jiad493. doi: 10.1093.
PubMed Abstract available

BENNETT C, Rivers EJ, Woo W, Bloch M, et al
Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
J Infect Dis. 2023 Nov 16:jiad508. doi: 10.1093.
PubMed Abstract available

HAIDAR G, Hodges JC, Bilderback A, Lukanski A, et al
Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
J Infect Dis. 2023 Nov 16:jiad511. doi: 10.1093.
PubMed Abstract available

DAVIES KA, Welch SR, Jain S, Sorvillo TE, et al
Fluorescent and Bioluminescent Reporter Mouse-Adapted Ebola Viruses Maintain Pathogenicity and Can Be Visualized in Vivo.
J Infect Dis. 2023;228.
PubMed Abstract available

MORI M, Doi T, Murata M, Moriyama Y, et al
Impact of nutritional status on antibody titer after booster mRNA COVID-19 vaccine among elderly adults in Japan.
J Infect Dis. 2023 Nov 14:jiad495. doi: 10.1093.
PubMed Abstract available

BUSHMAKER T, Feldmann F, Lovaglio J, Saturday G, et al
Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
J Infect Dis. 2023;228.
PubMed Abstract available

O'DONNELL KL, Callison J, Feldmann H, Hoenen T, et al
Single-Dose Treatment With Vesicular Stomatitis Virus-Based Ebola Virus Vaccine Expressing Ebola Virus-Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease.
J Infect Dis. 2023;228.
PubMed Abstract available

LASRADO N, Barouch DH
SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
J Infect Dis. 2023;228:1311-1313.
PubMed Abstract available

ZHONG S, Ng TWY, Skowronski DM, Iuliano AD, et al
Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status.
J Infect Dis. 2023 Nov 10:jiad497. doi: 10.1093.
PubMed Abstract available

POUKKA E, van Roekel C, Turunen T, Baum U, et al
Effectiveness of vaccines and monoclonal antibodies against respiratory syncytial virus: Generic protocol for register-based cohort study.
J Infect Dis. 2023 Nov 1:jiad484. doi: 10.1093.
PubMed Abstract available

October 2023

ASAMOAH-BOAHENG M, Grunau B, Karim ME, Kirkham TL, et al
The association of post-COVID-related symptoms and preceding SARS-CoV-2 infection among fully vaccinated paramedics in Canada.
J Infect Dis. 2023 Oct 31:jiad475. doi: 10.1093.
PubMed Abstract available

RUDOLPH AE, Khan FL, Shah A, Singh TG, et al
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy.
J Infect Dis. 2023 Oct 31:jiad474. doi: 10.1093.
PubMed Abstract available

HILL PC, Cobelens F, Martinez L, Garcia-Basteiro A, et al
Correspondence Regarding: McShane H. Improving TB vaccine trial efficiency: A tough nut to crack. J Infect Dis. 2023.
J Infect Dis. 2023 Oct 28:jiad466. doi: 10.1093.
PubMed

JAIROCE C, Macia D, Torres-Yaguana JP, Mayer L, et al
RTS, S/AS02A malaria vaccine-induced IgG responses equally recognize native-like fucosylated and non-fucosylated Plasmodium falciparum circumsporozoite proteins.
J Infect Dis. 2023 Oct 27:jiad471. doi: 10.1093.
PubMed Abstract available

TURCINOVIC J, Kuhfeldt K, Sullivan M, Landaverde L, et al
Transmission Dynamics and Rare Clustered Transmission Within an Urban University Population Before Widespread Vaccination.
J Infect Dis. 2023 Oct 19:jiad397. doi: 10.1093.
PubMed Abstract available

DUPREX WP, Dutch RE
Paramyxoviruses: Pathogenesis, Vaccines, Antivirals, and Prototypes for Pandemic Preparedness.
J Infect Dis. 2023;228.
PubMed Abstract available

DESCHAMPS AM, DeRocco AJ, Bok K, Patterson LJ, et al
Prototype Pathogens for Vaccine and Monoclonal Antibody Countermeasure Development: NIAID Workshop Process and Outcomes for Viral Families of Pandemic Potential.
J Infect Dis. 2023;228.
PubMed Abstract available

MORABITO KM, Cassetti MC, DeRocco AJ, Deschamps AM, et al
Viral Prototypes for Pandemic Preparedness: The Road Ahead.
J Infect Dis. 2023;228.
PubMed Abstract available

ADHIKARI EH, Lu P, Kang YJ, McDonald AR, et al
Diverging maternal and cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy.
J Infect Dis. 2023 Oct 10:jiad421. doi: 10.1093.
PubMed Abstract available

DE ARAUJO LP, Santos NCM, Corsetti PP, de Almeida LA, et al
Immunoinformatic approach for rational identification of immunogenic peptides against host entry and/or exit monkeypox proteins and potential multi-epitope vaccine construction.
J Infect Dis. 2023 Oct 7:jiad443. doi: 10.1093.
PubMed Abstract available

HSU FC, Pan LC, Huang YF, Yang CH, et al
A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers after Vaccination in a COVID-19 Convalescent Population.
J Infect Dis. 2023 Oct 5:jiad431. doi: 10.1093.
PubMed Abstract available

GREWAL R, Buchan SA, Nguyen L, Nasreen S, et al
Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >/=50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.
J Infect Dis. 2023 Oct 5:jiad419. doi: 10.1093.
PubMed Abstract available

CHIRENJE ZM, Laher F, Dintwe O, Muyoyeta M, et al
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis. 2023 Oct 5:jiad434. doi: 10.1093.
PubMed Abstract available

SKARBINSKI J, Nugent JR, Wood MS, Liu L, et al
Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study.
J Infect Dis. 2023;228:878-888.
PubMed Abstract available

ATMAR RL, Ettayebi K, Ramani S, Neill FH, et al
A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.
J Infect Dis. 2023 Oct 2:jiad401. doi: 10.1093.
PubMed Abstract available

September 2023

MADSEN AMR, Schaltz-Buchholzer F, Nielsen S, Benfield T, et al
Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: a randomized controlled trial.
J Infect Dis. 2023 Sep 29:jiad422. doi: 10.1093.
PubMed Abstract available

AMIN AB, Cates JE, Liu Z, Wu J, et al
Rotavirus genotypes in the post-vaccine era: A systematic review and meta-analysis of global, regional, and temporal trends in settings with and without rotavirus vaccine introduction.
J Infect Dis. 2023 Sep 21:jiad403. doi: 10.1093.
PubMed Abstract available

QURESHI H, Mahmood H, Sabry A, Hermez J, et al
Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
J Infect Dis. 2023;228.
PubMed Abstract available

LEROUX-ROELS I, Van Ranst M, Vandermeulen C, Abeele CV, et al
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
J Infect Dis. 2023 Sep 12:jiad321. doi: 10.1093.
PubMed Abstract available

FROBERG J, Koomen VJCH, van der Gaast-de Jongh CE, Philipsen R, et al
Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition.
J Infect Dis. 2023 Sep 7:jiad385. doi: 10.1093.
PubMed Abstract available

MARTIN JM, Moehling Geffel K, Ortiz MA, Rajasundaram D, et al
Differential Induction of Interferon Stimulated Genes by Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children During the 2018-19 Season.
J Infect Dis. 2023 Sep 4:jiad380. doi: 10.1093.
PubMed Abstract available

GRANT LR, Begier E, Theilacker C, Barry R, et al
Multicountry review of Streptococcus pneumoniae serotype distribution among adults with community-acquired pneumonia.
J Infect Dis. 2023 Sep 4:jiad379. doi: 10.1093.
PubMed Abstract available

Correction to: Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection.
J Infect Dis. 2023 Sep 1:jiad375. doi: 10.1093.
PubMed

August 2023

SARIOL A, Vickers MA, Christensen SM, Weiskopf D, et al
Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients.
J Infect Dis. 2023 Aug 25:jiad366. doi: 10.1093.
PubMed Abstract available

SUNG MH, Billings W, Carlock MA, Hanley HB, et al
Assessment of humoral immune responses to repeated influenza vaccination in a multiyear cohort: a five-year follow-up.
J Infect Dis. 2023 Aug 25:jiad319. doi: 10.1093.
PubMed Abstract available

LARIVIERE Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osang'ir B, et al
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
J Infect Dis. 2023 Aug 24:jiad350. doi: 10.1093.
PubMed Abstract available

HILL PC, Cobelens F, Martinez L, Behr MA, et al
An aspiration to radically shorten phase 3 TB vaccine trials.
J Infect Dis. 2023 Aug 22:jiad356. doi: 10.1093.
PubMed Abstract available

MCSHANE H
Improving TB vaccine trial efficiency: A tough nut to crack.
J Infect Dis. 2023 Aug 21:jiad360. doi: 10.1093.
PubMed

DONATO CM, Handley A, Byars SG, Bogdanovic-Sakran N, et al
"Vaccine take of RV3-BB rotavirus vaccine observed in Indonesian infants regardless of HBGA status".
J Infect Dis. 2023 Aug 18:jiad351. doi: 10.1093.
PubMed Abstract available

DUARTE LF, Vazquez Y, Diethelm-Varela B, Pavez V, et al
Differential Sars-Cov-2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough Subjects.
J Infect Dis. 2023 Aug 12:jiad320. doi: 10.1093.
PubMed Abstract available

KAPIL P, Wang Y, Zimmerman L, Gaykema M, et al
"Repeated B. pertussis Infections are Required to Reprogram Acellular Pertussis Vaccine-primed Host Responses in the Baboon Model".
J Infect Dis. 2023 Aug 11:jiad332. doi: 10.1093.
PubMed Abstract available

WANG FZ, Zhang CH, Tang L, Rodewald LE, et al
An observational prospective cohort study of vaccine effectiveness against SARS-CoV-2 infection of an aerosolized, inhaled adenovirus-type-5-vectored COVID-19 vaccine given as a second booster dose in Guangzhou city, China.
J Infect Dis. 2023 Aug 11:jiad338. doi: 10.1093.
PubMed Abstract available

NOBLE CC, Messina NL, Pittet LF, Curtis N, et al
Interpreting the results of trials of BCG vaccination for protection against COVID-19.
J Infect Dis. 2023 Aug 10:jiad316. doi: 10.1093.
PubMed Abstract available

ROUPHAEL NG, Branche AR, Diemert DJ, Falsey AR, et al
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
J Infect Dis. 2023 Aug 10:jiad323. doi: 10.1093.
PubMed Abstract available

YOON JG, Kim YE, Choi MJ, Choi WS, et al
Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database.
J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093.
PubMed Abstract available

HALL VG, Teh BW
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
J Infect Dis. 2023;228.
PubMed Abstract available

ANTINORI A, Bausch-Jurken M
The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
J Infect Dis. 2023;228.
PubMed Abstract available

BONANNI P, Ceddia F, Dawson R
A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
J Infect Dis. 2023;228.
PubMed Abstract available

SUBRAMANIAN V
Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
J Infect Dis. 2023;228.
PubMed Abstract available

ROUPHAEL N, Bausch-Jurken M
COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
J Infect Dis. 2023;228.
PubMed Abstract available

WILLICOMBE M
Foreword: Preventing COVID-19 Among the Immunocompromised Population.
J Infect Dis. 2023;228.
PubMed Abstract available

PARIS R
SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
J Infect Dis. 2023;228.
PubMed Abstract available

FINCKH A, Ciurea A, Raptis CE, Rubbert-Roth A, et al
Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
J Infect Dis. 2023;228.
PubMed Abstract available

LIU J, Cao F, Luo C, Guo Y, et al
Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies.
J Infect Dis. 2023 Aug 3:jiad306. doi: 10.1093.
PubMed Abstract available

BRAUNSTEIN SL, Wahnich A, Lazar R
COVID-19 outcomes among people with HIV and COVID-19 in New York City.
J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093.
PubMed Abstract available

REMICH S, Kitchin N, Peterson J, Li P, et al
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults 65 to 85 Years of Age.
J Infect Dis. 2023 Aug 2:jiad307. doi: 10.1093.
PubMed Abstract available

July 2023

POWELL JG, Goble SR, Debes JD
Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
PubMed Abstract available

KARRON RA, Luongo C, Woods S, Oliva J, et al
Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children.
J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093.
PubMed Abstract available

SAEZ-LLORENS X, Norero X, Mussi-Pinhata MM, Luciani K, et al
Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial.
J Infect Dis. 2023 Jul 21:jiad271. doi: 10.1093.
PubMed Abstract available

MALHERBE DC, Kimble JB, Atyeo C, Fischinger S, et al
A single dose intranasal combination panebolavirus vaccine.
J Infect Dis. 2023 Jul 20:jiad266. doi: 10.1093.
PubMed Abstract available

EL SAHLY HM, Yildirim I, Frey SE, Winokur P, et al
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
J Infect Dis. 2023 Jul 19:jiad276. doi: 10.1093.
PubMed Abstract available

MARZI A, Feldmann H
Marburg Virus Disease: Global Threat or Isolated Events?
J Infect Dis. 2023;228:103-105.
PubMed

JAGER M, Diem G, Sahanic S, Fux V, et al
Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
J Infect Dis. 2023;228:160-168.
PubMed Abstract available

ROA CC, de Los Reyes MRA, Plennevaux E, Smolenov I, et al
Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults.
J Infect Dis. 2023 Jul 13:jiad262. doi: 10.1093.
PubMed Abstract available

COMEAUX CA, Bart S, Bastian AR, Klyashtornyy V, et al
Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
J Infect Dis. 2023 Jul 11:jiad220. doi: 10.1093.
PubMed Abstract available

FERNANDEZ-GONZALEZ M, Agullo V, Garcia JA, Padilla S, et al
T-cell immunity against SARS-CoV-2 measured by an interferon-gamma release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants.
J Infect Dis. 2023 Jul 7:jiad260. doi: 10.1093.
PubMed Abstract available

June 2023

PAULSEN GC, Frenck R, Tomashek KM, Alarcon RM, et al
Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: a Randomized, Controlled Phase 1 Study.
J Infect Dis. 2023 Jun 28:jiad235. doi: 10.1093.
PubMed Abstract available

FUJITA S, Uriu K, Pan L, Nao N, et al
Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model.
J Infect Dis. 2023 Jun 27:jiad230. doi: 10.1093.
PubMed Abstract available

SALEEM AF, Parkar S, Zehra SM, Kazi Z, et al
Two-year duration of immunity of inactivated poliovirus vaccine: A follow-up study in Pakistan in 2020.
J Infect Dis. 2023 Jun 27:jiad237. doi: 10.1093.
PubMed Abstract available

MANDOLO J, Parker EPK, Bronowski C, Sindhu KNC, et al
Association between maternal breastmilk microbiota composition and rotavirus vaccine response in African, Asian, and European infants: a prospective cohort study.
J Infect Dis. 2023 Jun 26:jiad234. doi: 10.1093.
PubMed Abstract available

VOORMAN A, Lyons H, Shuab F, Adamu US, et al
Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria.
J Infect Dis. 2023 Jun 26:jiad222. doi: 10.1093.
PubMed Abstract available

WOOLSEY C, Strampe J, Fenton KA, Agans KN, et al
A recombinant vesicular stomatitis virus-based vaccine provides postexposure protection against Bundibugyo ebolavirus infection.
J Infect Dis. 2023 Jun 8:jiad207. doi: 10.1093.
PubMed Abstract available

MARZI A, Feldmann F, O'Donnell KL, Hanley PW, et al
Preexisting immunity does not prevent efficacy of VSV-based filovirus vaccines in nonhuman primates.
J Infect Dis. 2023 Jun 8:jiad208. doi: 10.1093.
PubMed Abstract available

EMBACHER S, Maertens K, Herzog SA
Half-life estimation of pertussis-specific maternal antibodies in (pre)term infants after in-pregnancy tetanus, diphtheria, acellular pertussis vaccination.
J Infect Dis. 2023 Jun 7:jiad212. doi: 10.1093.
PubMed Abstract available

WANG W, Goguet E, Paz Padilla S, Vassell R, et al
Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.
J Infect Dis. 2023 Jun 6:jiad111. doi: 10.1093.
PubMed Abstract available

REYES Y, St Jean DT, Bowman NM, Gonzalez F, et al
Non-secretor phenotype is associated with less risk of rotavirus-associated acute gastroenteritis in a vaccinated Nicaraguan birth cohort.
J Infect Dis. 2023 Jun 5:jiad202. doi: 10.1093.
PubMed Abstract available

May 2023

WEI F, Alberts CJ, Albuquerque A, Clifford GM, et al
Impact of human papillomavirus vaccine against anal human papillomavirus infection, anal intraepithelial neoplasia, and recurrence of anal intraepithelial neoplasia: a systematic review and meta-analysis.
J Infect Dis. 2023 May 31:jiad183. doi: 10.1093.
PubMed Abstract available

KEELEY AJ, Groves D, Armitage EP, Senghore E, et al
Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses.
J Infect Dis. 2023 May 29:jiad153. doi: 10.1093.
PubMed Abstract available

SCHALTZ-BUCHHOLZER F, Aaby P, Silva I, Monteiro I, et al
Mortality Risk Among Frail Neonates and Maternal BCG Vaccine Scar Status: Observational Study From Guinea-Bissau.
J Infect Dis. 2023;227:1237-1244.
PubMed Abstract available

FRIES L, Formica N, Mallory RM, Zhou H, et al
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination.
J Infect Dis. 2023 May 21:jiad163. doi: 10.1093.
PubMed Abstract available

XIA X, Tan ZM, Wan P, Zheng H, et al
Environmental impact assessment for the use of an orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine in randomised clinical trials.
J Infect Dis. 2023 May 18:jiad134. doi: 10.1093.
PubMed Abstract available

WOOLSEY C, Borisevich V, Agans KN, O'Toole R, et al
A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus.
J Infect Dis. 2023 May 12:jiad157. doi: 10.1093.
PubMed Abstract available

MORAIS S, Wissing MD, Khosrow-Khavar F, Burchell AN, et al
Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study.
J Infect Dis. 2023;227:1173-1184.
PubMed Abstract available

WEINBERG A, Schmid DS, Leung J, Johnson MJ, et al
Predictors of Five-Year Persistence of Antibody Responses to Zoster Vaccines.
J Infect Dis. 2023 May 4:jiad132. doi: 10.1093.
PubMed Abstract available

ASSANTACHAI P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, et al
Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.
J Infect Dis. 2023 May 4:jiad133. doi: 10.1093.
PubMed Abstract available

April 2023

SINGH G, Abbad A, Tcheou J, Mendu DR, et al
Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections.
J Infect Dis. 2023 Apr 27:jiad116. doi: 10.1093.
PubMed Abstract available

IONESCU IG, Skowronski DM, Sauvageau C, Chuang E, et al
BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration.
J Infect Dis. 2023;227:1073-10783.
PubMed Abstract available

ALVAREZ-HEREDIA P, Reina-Alfonso I, Dominguez-Del Castillo JJ, Gutierrez-Gonzalez C, et al
Accelerated T cell immunosenescence in CMV-seropositive individuals after SARS-CoV-2 infection.
J Infect Dis. 2023 Apr 26:jiad119. doi: 10.1093.
PubMed Abstract available

HOEVE CE, de Gier B, Huiberts AJ, de Melker HE, et al
Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022.
J Infect Dis. 2023 Apr 24:jiad110. doi: 10.1093.
PubMed Abstract available

JORDAN E, Kabir G, Schultz S, Silbernagl G, et al
Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: a Human Challenge Trial of MVA-BN-RSV Vaccine.
J Infect Dis. 2023 Apr 20:jiad108. doi: 10.1093.
PubMed Abstract available

Correction to: Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men.
J Infect Dis. 2023 Apr 19:jiad097. doi: 10.1093.
PubMed

BUBAK AN, Coughlan C, Posey J, Saviola AJ, et al
Zoster-Associated Prothrombotic Plasma Exosomes and Increased Stroke Risk.
J Infect Dis. 2023;227:993-1001.
PubMed Abstract available

BLANKSON JN
Bivalent COVID Vaccines; Can the Original Antigenic Sin be Forgiven?
J Infect Dis. 2023 Apr 5:jiad073. doi: 10.1093.
PubMed

EL-HENEIDY A, Grimwood K, Lambert SB, Ware RS, et al
Interference between enteric viruses and live-attenuated rotavirus vaccine virus in a healthy Australian birth cohort.
J Infect Dis. 2023 Apr 4:jiad094. doi: 10.1093.
PubMed Abstract available

TANG L, Wang FZ, Rodewald LE, Wang XY, et al
Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
J Infect Dis. 2023 Apr 3:jiad090. doi: 10.1093.
PubMed Abstract available

March 2023

XIANG J, Chang Q, McLinden JH, Bhattarai N, et al
Characterization of "off-target" immune modulation induced by live attenuated yellow fever vaccine.
J Infect Dis. 2023 Mar 30:jiad086. doi: 10.1093.
PubMed Abstract available

VAN EER K, Middeldorp M, Dzebisasjvili T, Lamkaraf N, et al
Effects of two and three vaccinations with the bivalent HPV vaccine on the prevalence and load of HPV in clearing and persistent infections in young women.
J Infect Dis. 2023 Mar 29:jiad080. doi: 10.1093.
PubMed Abstract available

NURMI V, Knight C, Estcourt L, Hepojoki J, et al
The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors.
J Infect Dis. 2023 Mar 27:jiad070. doi: 10.1093.
PubMed Abstract available

SMITH CL, Bednarchik B, Aung H, Wilk DJ, et al
Humoral and Cellular Immunity Induced by Adjuvanted and Standard Trivalent Influenza Vaccine in Older Nursing Home Residents.
J Infect Dis. 2023 Mar 23:jiad071. doi: 10.1093.
PubMed Abstract available

WHITE JL, Grabowski MK, Rositch AF, Gravitt PE, et al
Trends in adolescent human papillomavirus vaccination and parental hesitancy in the United States.
J Infect Dis. 2023 Mar 3:jiad055. doi: 10.1093.
PubMed Abstract available

SUN P, Balinsky CA, Jiang L, Jani V, et al
Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty U.S. Navy Sailors and Marines.
J Infect Dis. 2023 Mar 1:jiad054. doi: 10.1093.
PubMed Abstract available

RAADSEN MP, Dahlke C, Fathi A, Lamers MM, et al
Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein.
J Infect Dis. 2023 Mar 1:jiad052. doi: 10.1093.
PubMed Abstract available

TILEY KS, Ratcliffe H, Voysey M, Jefferies K, et al
Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C.
J Infect Dis. 2023;227:610-621.
PubMed Abstract available

February 2023

CORTESE MM, Taylor AW, Akinbami LJ, Thames-Allen A, et al
Surveillance for multisystem inflammatory syndrome in U.S. children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021-March 2022.
J Infect Dis. 2023 Feb 23:jiad051. doi: 10.1093.
PubMed Abstract available

BOZIO CH, Butterfield KA, Briggs Hagen M, Grannis S, et al
Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance.
J Infect Dis. 2023 Feb 18:jiad040. doi: 10.1093.
PubMed Abstract available

HUAPAYA JA, Higgins J, Kanth S, Demirkale C, et al
Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
J Infect Dis. 2023 Feb 18:jiad045. doi: 10.1093.
PubMed Abstract available

ALTHAUS T, Landier J, Zhu F, Raps H, et al
The impact of SARS-CoV-2 vaccination and infection on neutralising antibodies: a nation-wide cross-sectional analysis.
J Infect Dis. 2023 Feb 14:jiad030. doi: 10.1093.
PubMed Abstract available

HITCHINGS MDT, Borgert BA, Shir A, Yang B, et al
Dynamics of anti-influenza mucosal IgA over a season in a cohort of individuals living or working in a long-term care facility.
J Infect Dis. 2023 Feb 6:jiad029. doi: 10.1093.
PubMed Abstract available

DESANTIS SM, Yaseen A, Hao T, Leon-Novelo L, et al
Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: A population-based survey of 22,575 participants.
J Infect Dis. 2023 Feb 2:jiad020. doi: 10.1093.
PubMed Abstract available

BEBIA Z, Reyes O, Jeanfreau R, Kantele A, et al
Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.
J Infect Dis. 2023 Feb 1:jiad024. doi: 10.1093.
PubMed Abstract available

January 2023

THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
PubMed

ORTIZ JR, Bernstein DI, Hoft DF, Woods CW, et al
A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults.
J Infect Dis. 2023 Jan 26:jiad021. doi: 10.1093.
PubMed Abstract available

TENFORDE MW, Weber ZA, DeSilva MB, Stenehjem E, et al
Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network.
J Infect Dis. 2023 Jan 23:jiad015. doi: 10.1093.
PubMed Abstract available

CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
Vaccine effectiveness against 12-month incident and persistent anal human papillomavirus infection among gay, bisexual, and other men who have sex with men.
J Infect Dis. 2023 Jan 19:jiad005. doi: 10.1093.
PubMed Abstract available

GRAY EJ, Cooper LV, Bandyopadhyay AS, Blake IM, et al
The origins and risk factors for serotype-2 vaccine-derived poliovirus (VDPV2) emergences in Africa during 2016-2019.
J Infect Dis. 2023 Jan 11:jiad004. doi: 10.1093.
PubMed Abstract available

PEEBLES K, Arciuolo RJ, Romano AS, Sell J, et al
Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, January-June 2021.
J Infect Dis. 2023 Jan 10:jiac448. doi: 10.1093.
PubMed Abstract available

December 2022

GREGG KA, Wang Y, Warfel J, Schoenfeld E, et al
"Antigen Discovery for Next-Generation Pertussis Vaccines using Immunoproteomics and Transposon Directed Insertion Sequencing".
J Infect Dis. 2022 Dec 28:jiac502. doi: 10.1093.
PubMed Abstract available

NAKAGAMA Y, Candray K, Kaku N, Komase Y, et al
Antibody avidity maturation, following recovery from infection or the booster vaccination, grants breadth in SARS-CoV-2 neutralizing capacity.
J Infect Dis. 2022 Dec 22:jiac492. doi: 10.1093.
PubMed Abstract available

DOUROS A, Ante Z, Suissa S, Brassard P, et al
Common vaccines and the risk of incident dementia: a population-based cohort study.
J Infect Dis. 2022 Dec 21:jiac484. doi: 10.1093.
PubMed Abstract available

SALMON DA, Black S, Didierlaurent AM, Moulton LH, et al
Commentary on "Common vaccines and the risk of dementia: a population-based cohort study": Science can be messy but eventually leads to truths.
J Infect Dis. 2022 Dec 21:jiac487. doi: 10.1093.
PubMed

MAYNARD-SMITH L, Derrick JP, Borrow R, Lucidarme J, et al
Genome-Wide Association Studies Identify an Association of Transferrin Binding Protein B Variation and Invasive Serogroup Y Meningococcal Disease in Older Adults.
J Infect Dis. 2022;226:2204-2214.
PubMed Abstract available

REICHERZ F, Xu RY, Abu-Raya B, Majdoubi A, et al
Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic.
J Infect Dis. 2022;226:2064-2068.
PubMed Abstract available

DIEZ-DOMINGO J, Saez-Llorens X, Rodriguez-Weber MA, Epalza C, et al
Safety and immunogenicity of a ChAd155-vectored RSV vaccine (ChAd155-RSV) in healthy RSV-seropositive children 12-23 months of age.
J Infect Dis. 2022 Dec 9:jiac481. doi: 10.1093.
PubMed Abstract available

ACOSTA CJ, Diaz C, Nordio F, Han HH, et al
Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-Up Compared With Natural Infection.
J Infect Dis. 2022 Dec 9:jiac482. doi: 10.1093.
PubMed Abstract available

Correction to: "Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2".
J Infect Dis. 2022 Dec 8:jiac429. doi: 10.1093.
PubMed

SHIODA K, Chen Y, Collins MH, Lopman BA, et al
Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution of Naturally Acquired Immunity.
J Infect Dis. 2022 Dec 7:jiac483. doi: 10.1093.
PubMed Abstract available

NASCIMENTO EJM, Norwood B, Kpamegan E, Parker A, et al
Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine are Functional in Activating the Complement System.
J Infect Dis. 2022 Dec 3:jiac476. doi: 10.1093.
PubMed Abstract available

GREWAL R, Nguyen L, Buchan SA, Wilson SE, et al
Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada.
J Infect Dis. 2022 Dec 3:jiac468. doi: 10.1093.
PubMed Abstract available

November 2022

STIRRUP O, Krutikov M, Tut G, Palmer T, et al
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
J Infect Dis. 2022;226:1877-1881.
PubMed Abstract available

MONTO AS, Lauring AS, Martin ET
SARS-CoV-2 Vaccine Strain Selection: Guidance from Influenza.
J Infect Dis. 2022 Nov 25:jiac454. doi: 10.1093.
PubMed Abstract available

VANNIER E, Richer LM, Dinh DM, Brisson D, et al
Deployment of a reservoir-targeted vaccine against Borreliella burgdorferi reduces the prevalence of Babesia microti coinfection in Ixodes scapularis ticks.
J Infect Dis. 2022 Nov 23:jiac462. doi: 10.1093.
PubMed Abstract available

WANG X, Zein J, Ji X, Lin DY, et al
Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
PubMed Abstract available

DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
PubMed Abstract available

TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
PubMed Abstract available

ILCHMANN H, Samy N, Reichhardt D, Schmidt D, et al
Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic(R) induce durable B cell memory responses comparable to replicating smallpox vaccines.
J Infect Dis. 2022 Nov 21:jiac455. doi: 10.1093.
PubMed Abstract available

LIND ML, Copin R, McCarthy S, Coppi A, et al
Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
PubMed Abstract available

JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
PubMed Abstract available

EIDEN J, Fierro C, Schwartz H, Adams M, et al
Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
J Infect Dis. 2022 Nov 9. pii: 6807529. doi: 10.1093.
PubMed Abstract available

STIEH DJ, Barouch DH, Comeaux C, Sarnecki M, et al
Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study.
J Infect Dis. 2022 Nov 9. pii: 6812747. doi: 10.1093.
PubMed Abstract available

JAGER M, Dichtl S, Bellmann-Weiler R, Reindl M, et al
Serum neutralization against SARS-CoV-2 variants is heterogenic and depends on vaccination regimen.
J Infect Dis. 2022 Nov 1. pii: 6783141. doi: 10.1093.
PubMed Abstract available

KUO TY, Lien CE, Lin YJ, Lin MY, et al
Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
J Infect Dis. 2022;226:1562-1567.
PubMed Abstract available

MIDDLETON BF, Danchin M, Jones MA, Leach AJ, et al
Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial.
J Infect Dis. 2022;226:1537-1544.
PubMed Abstract available

October 2022

DE SILVA A, White L
Immunogenicity of a live dengue vaccine (TAK-003).
J Infect Dis. 2022 Oct 26. pii: 6774399. doi: 10.1093.
PubMed

ROE MK, Perez MA, Hsiao HM, Lapp SA, et al
An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.
J Infect Dis. 2022 Oct 25. pii: 6770706. doi: 10.1093.
PubMed Abstract available

LEUNG J, Dooling K, Marin M, Anderson TC, et al
The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch.
J Infect Dis. 2022;226.
PubMed Abstract available

MARIN M, Leung J, Anderson TC, Lopez AS, et al
Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.
J Infect Dis. 2022;226.
PubMed Abstract available

WILLIS ED, Marko AM, Rasmussen SA, McGee M, et al
Merck/Centers for Disease Control and Prevention Varicella Vaccine Pregnancy Registry: 19-Year Summary of Data From Inception Through Closure, 1995-2013.
J Infect Dis. 2022;226.
PubMed Abstract available

ARVIN AM
Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.
J Infect Dis. 2022;226.
PubMed Abstract available

MARIN M, Lopez AS, Melgar M, Dooling K, et al
Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.
J Infect Dis. 2022;226.
PubMed Abstract available

LEUNG J, Lopez AS, Marin M
Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019.
J Infect Dis. 2022;226.
PubMed Abstract available

DOLLARD S, Chen MH, Lindstrom S, Marin M, et al
Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem.
J Infect Dis. 2022;226.
PubMed Abstract available

DREES M, Weber DJ
Prevention and Control of Nosocomial Varicella During the United States Varicella Vaccination Program Era.
J Infect Dis. 2022;226.
PubMed Abstract available

ELAM-EVANS LD, Valier MR, Fredua B, Zell E, et al
Celebrating 25 Years of Varicella Vaccination Coverage for Children and Adolescents in the United States: A Success Story.
J Infect Dis. 2022;226.
PubMed Abstract available

ZHOU F, Leung J, Marin M, Dooling KL, et al
Health and Economic Impact of the United States Varicella Vaccination Program, 1996-2020.
J Infect Dis. 2022;226.
PubMed Abstract available

MORO PL, Leung J, Marquez P, Kim Y, et al
Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
J Infect Dis. 2022;226.
PubMed Abstract available

MARIN M, Seward JF, Gershon AA
25 Years of Varicella Vaccination in the United States.
J Infect Dis. 2022;226.
PubMed

SHAPIRO ED, Marin M
The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States.
J Infect Dis. 2022;226.
PubMed Abstract available

DOOLING K, Marin M, Gershon AA
Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
J Infect Dis. 2022;226.
PubMed Abstract available

ANDERSON M, Stec M, Gosha A, Mohammad T, et al
Longitudinal SARS-CoV-2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid IgG.
J Infect Dis. 2022 Oct 20. pii: 6764413. doi: 10.1093.
PubMed Abstract available

LAAKE I, Skodvin SN, Blix K, Caspersen IH, et al
Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort.
J Infect Dis. 2022 Oct 19. pii: 6763324. doi: 10.1093.
PubMed Abstract available

STUART A, Virta M, Williams K, Seppa I, et al
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
J Infect Dis. 2022 Oct 19. pii: 6763323. doi: 10.1093.
PubMed Abstract available

AGALLOU M, Koutsoni OS, Michail M, Zisimopoulou P, et al
Antibody and T cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2.
J Infect Dis. 2022 Oct 19. pii: 6763327. doi: 10.1093.
PubMed Abstract available

BADIZADEGAN K, Kalkowska DA, Thompson KM
Polio by the Numbers-A Global Perspective.
J Infect Dis. 2022;226:1309-1318.
PubMed Abstract available

SHOVER CL, Rosen A, Mata J, Robie B, et al
Engaging Same-Day Peer Ambassadors to Increase Coronavirus Disease 2019 Vaccination Among People Experiencing Unsheltered Homelessness in Los Angeles County: A Hybrid Feasibility-Evaluation Study.
J Infect Dis. 2022;226.
PubMed Abstract available

GIBSON C, Schumann C, Neuschel K, McBride JA, et al
COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
J Infect Dis. 2022;226.
PubMed Abstract available

RUDMANN KC, Brown NE, Rubis AB, Burns M, et al
Invasive Meningococcal Disease Among People Experiencing Homelessness-United States, 2016-2019.
J Infect Dis. 2022;226.
PubMed Abstract available

BENET S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreno-Lopez N, et al
Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
J Infect Dis. 2022 Oct 6. pii: 6749018. doi: 10.1093.
PubMed Abstract available

CHAN CEZ, Wong SKK, Yazid NBM, Ng OT, et al
Residual humoral immunity sustained over decades in a cohort of vaccinia-vaccinated individuals.
J Infect Dis. 2022 Oct 6. pii: 6749013. doi: 10.1093.
PubMed Abstract available

ASAMOAH-BOAHENG M, Goldfarb DM, Karim ME, O'Brien SF, et al
The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
J Infect Dis. 2022 Oct 5. pii: 6748952. doi: 10.1093.
PubMed Abstract available

September 2022

FURUKAWA K, Kurahashi Y, Ishimaru H, Nishimura M, et al
The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant.
J Infect Dis. 2022 Sep 26. pii: 6717967. doi: 10.1093.
PubMed

AMANO M, Otsu S, Ichikawa Y, Higashi-Kuwata N, et al
Restoration of neutralization activity against Omicrons BA.2 and BA.5 in older adults and individuals with risk factors following the 4th-dose of SARS-CoV-2 BNT162b2 vaccine.
J Infect Dis. 2022 Sep 22. pii: 6711120. doi: 10.1093.
PubMed

LUNA-MUSCHI A, Noguera SV, Borges IC, De Paula AV, et al
Characterization of SARS-CoV-2 Omicron variant shedding and predictors of viral culture positivity on vaccinated healthcare workers with mild COVID-19.
J Infect Dis. 2022 Sep 22. pii: 6711076. doi: 10.1093.
PubMed Abstract available

BRAZER N, Morris MK, Servellita V, Anglin K, et al
Neutralizing immunity induced against the Omicron BA.1 and BA.2 variants in vaccine breakthrough infections.
J Infect Dis. 2022 Sep 22. pii: 6711075. doi: 10.1093.
PubMed Abstract available

KLUGMAN KP, Rodgers GL
Pneumococcal carriage and sero-epidemiology studies to measure current and future pneumococcal conjugate vaccine effectiveness.
J Infect Dis. 2022 Sep 21. pii: 6710232. doi: 10.1093.
PubMed

ROSSLER A, Kimpel J, Fleischer V, Huber S, et al
Regimen of COVID-19 vaccination influences extent and kinetics of antibody avidity.
J Infect Dis. 2022 Sep 16. pii: 6701886. doi: 10.1093.
PubMed Abstract available

COWLING BJ, Cheng SMS, Martin-Sanchez M, Au NYM, et al
Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine.
J Infect Dis. 2022 Sep 15. pii: 6701635. doi: 10.1093.
PubMed Abstract available

KU JH, Levin MJ, Luo Y, Florea A, et al
Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System.
J Infect Dis. 2022;226:757-765.
PubMed Abstract available

GOLDSTEIN N, Bockstal V, Bart S, Luhn K, et al
Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
J Infect Dis. 2022;226:595-607.
PubMed Abstract available

YANG B, Wong IOL, Xiao J, Tsang TK, et al
Effectiveness of CoronaVac and BNT162b2 vaccine against SARS-CoV-2 Omicron BA.2 infections in Hong Kong.
J Infect Dis. 2022 Sep 2. pii: 6687716. doi: 10.1093.
PubMed Abstract available

August 2022

SHAW AG, Cooper LV, Gumede N, Bandyopadhyay AS, et al
Time Taken to Detect and Respond to Polio Outbreaks in Africa and the Potential Impact of Direct Molecular Detection and Nanopore Sequencing.
J Infect Dis. 2022;226:453-462.
PubMed Abstract available

SADOFF J, De Paepe E, DeVincenzo J, Gymnopoulou E, et al
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
J Infect Dis. 2022;226:396-406.
PubMed Abstract available

BEALL B, Chochua S, Li Z, Tran T, et al
Invasive Pneumococcal Disease Clusters Disproportionally Impact Persons Experiencing Homelessness, Injecting Drug Users, and the Western United States.
J Infect Dis. 2022;226:332-341.
PubMed Abstract available

TORNELL A, Grauers Wiktorin H, Ringlander J, Arabpour M, et al
Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood.
J Infect Dis. 2022;226:208-216.
PubMed Abstract available

QUACH HQ, Chen J, Monroe JM, Ratishvili T, et al
The influence of sex, BMI, and age on cellular and humoral immune responses against measles after a 3rd dose of MMR vaccine.
J Infect Dis. 2022 Aug 22. pii: 6673362. doi: 10.1093.
PubMed Abstract available

MIYAKAWA K, Kato H, Ohtake N, Stanleyraj Jeremiah S, et al
Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
J Infect Dis. 2022 Aug 18. pii: 6670905. doi: 10.1093.
PubMed Abstract available

GOMEZ GB, Nelson CB, Rizzo C, Shepard DS, et al
Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
J Infect Dis. 2022;226.
PubMed Abstract available

HOA LNM, Sullivan SG, Mai LQ, Khvorov A, et al
Influenza A(H1N1)pdm09 But Not A(H3N2) Virus Infection Induces Durable Seroprotection: Results From the Ha Nam Cohort.
J Infect Dis. 2022;226:59-69.
PubMed Abstract available

CRAVENS M, Alugupalli AS, Sandilya VK, McGeady SJ, et al
The IgM response to pneumococcal polysaccharide vaccine is sufficient for conferring immunity.
J Infect Dis. 2022 Aug 6. pii: 6657690. doi: 10.1093.
PubMed Abstract available

GREBE E, Yu EA, Bravo MD, Welte A, et al
COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
J Infect Dis. 2022 Aug 3. pii: 6654836. doi: 10.1093.
PubMed Abstract available

July 2022

VIVALDI G, Jolliffe DA, Faustini S, Shields AM, et al
Correlation between post-vaccination anti-Spike antibody titres and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study.
J Infect Dis. 2022 Jul 30. pii: 6652292. doi: 10.1093.
PubMed Abstract available

LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
PubMed Abstract available

KNOLL MD, Bennett JC, Yang Y, Quesada MG, et al
Challenges inferring pneumococcal conjugate vaccine impact from bacterial surveillance data.
J Infect Dis. 2022 Jul 28. pii: 6650942. doi: 10.1093.
PubMed

CHU WM, Lee YH, Cheng-Chung Wei J, Lee YH, et al
Comment on Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
J Infect Dis. 2022 Jul 26. pii: 6649924. doi: 10.1093.
PubMed

CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
PubMed Abstract available

MAHANT A, Guerguis S, Blevins TP, Cheshenko N, et al
Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
J Infect Dis. 2022 Jul 14. pii: 6644507. doi: 10.1093.
PubMed Abstract available

BRADFUTE S, Mertz G
Immune responses to herpes simplex virus infection: implications for vaccine development.
J Infect Dis. 2022 Jul 8. pii: 6633820. doi: 10.1093.
PubMed

WAGNER AL, Sanchez N, Kubale J, Kuan G, et al
Single dose vaccination among infants and toddlers provides modest protection against influenza illness which wanes after 5 months.
J Infect Dis. 2022 Jul 7. pii: 6633354. doi: 10.1093.
PubMed Abstract available

COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
PubMed

ASSAWAKOSRI S, Suntronwong N, Yorsaeng R, Kanokudom S, et al
Breakthrough infection by SARS-CoV-2 Delta and Omicron variants elicited immune response comparable to mRNA booster vaccination.
J Infect Dis. 2022 Jul 5. pii: 6631219. doi: 10.1093.
PubMed

REN Z, Sun R, Cui G, Wang H, et al
Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants.
J Infect Dis. 2022 Jul 5. pii: 6631218. doi: 10.1093.
PubMed

NYOMBAYIRE J, Ingabire R, Magod B, Mazzei A, et al
Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
J Infect Dis. 2022 Jul 1. pii: 6625827. doi: 10.1093.
PubMed Abstract available

June 2022

DEMASO CR, Karwal L, Zahralban-Steele M, Dominguez D, et al
Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue Vaccine.
J Infect Dis. 2022 Jun 30. pii: 6623496. doi: 10.1093.
PubMed Abstract available

VENCALEK O, Beran J, Furst T, Kratka Z, et al
Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
J Infect Dis. 2022 Jun 28. pii: 6619238. doi: 10.1093.
PubMed

LLIBRE JM, Revollo B, Aguilar S, Calomarde-Gomez C, et al
Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
J Infect Dis. 2022 Jun 28. pii: 6619237. doi: 10.1093.
PubMed

MOY JN, Anderson M, Shen X, Fu J, et al
Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 Vaccine in Infection-Naive and Previously-Infected Individuals.
J Infect Dis. 2022 Jun 27. pii: 6618640. doi: 10.1093.
PubMed Abstract available

AMJADI MF, Adyniec RR, Gupta S, Bashar SJ, et al
Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination.
J Infect Dis. 2022 Jun 27. pii: 6618636. doi: 10.1093.
PubMed Abstract available

MOODIE Z, Dintwe O, Sawant S, Grove D, et al
Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.
J Infect Dis. 2022 Jun 27. pii: 6618597. doi: 10.1093.
PubMed Abstract available

STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
PubMed Abstract available

CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
PubMed Abstract available

VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
PubMed Abstract available

GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
PubMed Abstract available

LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
PubMed Abstract available

DONATO CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, et al
Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.
J Infect Dis. 2022;225:2116-2126.
PubMed Abstract available

SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
PubMed Abstract available

JACOBSON JM
Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
PubMed

LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
PubMed Abstract available

STORCH GA
Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
PubMed

May 2022

ROSTAD CA, Chen X, Sun HY, Hussaini L, et al
Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination.
J Infect Dis. 2022 May 26. pii: 6593309. doi: 10.1093.
PubMed Abstract available

OSTER G, Bornheimer R, Ottino K
Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
PubMed

NALIN D
Cholera control requires reducing mortality along with vaccination programs.
J Infect Dis. 2022 May 18. pii: 6588066. doi: 10.1093.
PubMed

AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.
PubMed

AZIZ AB, Verma H, Jeyaseelan V, Md Y, et al
One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomized clinical trial in Bangladesh.
J Infect Dis. 2022 May 16. pii: 6586252. doi: 10.1093.
PubMed Abstract available

FAUSTHER-BOVENDO H, Qiu X, Babuadze GG, Azizi H, et al
Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
J Infect Dis. 2022;225:1852-1855.
PubMed Abstract available

BABER J, Arya M, Moodley Y, Jaques A, et al
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
PubMed Abstract available

MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
PubMed Abstract available

EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
PubMed Abstract available

MUHR LSA, Eklund C, Lagheden C, Eriksson T, et al
Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
J Infect Dis. 2022 May 10. pii: 6582940. doi: 10.1093.
PubMed Abstract available

LIU B, Stepien S, Pye V, Law C, et al
High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
PubMed Abstract available

KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
PubMed Abstract available

MITSI E, McLenaghan D, Wolf AS, Jones S, et al
Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
J Infect Dis. 2022;225:1626-1631.
PubMed Abstract available

SIRIVICHAYAKUL C, Barranco-Santana EA, Rivera IE, Kilbury J, et al
Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
J Infect Dis. 2022;225:1513-1520.
PubMed Abstract available

April 2022

SMID M, Berec L, Pribylova L, Majek O, et al
Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
J Infect Dis. 2022 Apr 28. pii: 6575414. doi: 10.1093.
PubMed Abstract available

TJAN LH, Furukawa K, Kurahashi Y, Sutandhio S, et al
As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
J Infect Dis. 2022 Apr 28. pii: 6575227. doi: 10.1093.
PubMed

BAJEMA KL, Gierke R, Farley MM, Schaffner W, et al
Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States.
J Infect Dis. 2022 Apr 28. pii: 6575225. doi: 10.1093.
PubMed Abstract available

ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Puenpa J, et al
Omicron BA.1, BA.2 and COVID-19 booster vaccination.
J Infect Dis. 2022 Apr 27. pii: 6575160. doi: 10.1093.
PubMed

OKUDA M, Sakai-Tagawa Y, Koga M, Koibuchi T, et al
Immunological correlates of prevention of the onset of seasonal H3N2 influenza.
J Infect Dis. 2022 Apr 27. pii: 6574940. doi: 10.1093.
PubMed Abstract available

LIN DY, Zeng D, Gu Y, Krause PR, et al
Reliably Assessing Duration of Protection for COVID-19 Vaccines.
J Infect Dis. 2022 Apr 21. pii: 6571630. doi: 10.1093.
PubMed Abstract available

SKOWRONSKI DM, Leir S, Sabaiduc S, Chambers C, et al
Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
J Infect Dis. 2022;225:1387-1398.
PubMed Abstract available

BROKAW A, Nguyen S, Quach P, Orvis A, et al
A recombinant alpha-like protein subunit vaccine (GBS-NN) provides protection in murine models of Group B Streptococcus infection.
J Infect Dis. 2022 Apr 16. pii: 6569354. doi: 10.1093.
PubMed Abstract available

ZHU KL, Gao HX, Yao L, Rong J, et al
Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron.
J Infect Dis. 2022 Apr 16. pii: 6569353. doi: 10.1093.
PubMed Abstract available

LE GARS M, Sadoff J, Struyf F, Heerwegh D, et al
Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
J Infect Dis. 2022 Apr 16. pii: 6569363. doi: 10.1093.
PubMed Abstract available

BOLOTIN S, Osman S, Hughes SL, Ariyarajah A, et al
In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis.
J Infect Dis. 2022 Apr 13. pii: 6568034. doi: 10.1093.
PubMed Abstract available

PERMAR SR, Kaur A, Fruh K
De-risking human cytomegalovirus vaccine clinical development in relevant preclinical models.
J Infect Dis. 2022 Apr 13. pii: 6567687. doi: 10.1093.
PubMed

LI J, Wellnitz S, Chi XS, Yue Y, et al
Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses.
J Infect Dis. 2022 Apr 12. pii: 6567520. doi: 10.1093.
PubMed Abstract available

KWON JH, Tenforde MW, Gaglani M, Talbot HK, et al
mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients.
J Infect Dis. 2022 Apr 6. pii: 6564370. doi: 10.1093.
PubMed Abstract available

XIONG W, Tsang TK, Perera RAPM, Leung NHL, et al
Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children.
J Infect Dis. 2022 Apr 5. pii: 6563665. doi: 10.1093.
PubMed Abstract available

CARR OJJ, Vilivong K, Bounvilay L, Dunne EM, et al
Nasopharyngeal Pneumococcal Colonization Density Is Associated With Severe Pneumonia in Young Children in the Lao People's Democratic Republic.
J Infect Dis. 2022;225:1266-1273.
PubMed Abstract available

March 2022

ITSKO M, Topaz N, Ousmane S, Popoola M, et al
Enhancing meningococcal genomic surveillance in the meningitis belt using high-resolution culture-free whole genome sequencing.
J Infect Dis. 2022 Mar 24. pii: 6553907. doi: 10.1093.
PubMed Abstract available

MARON JS, Conroy M, Naranbai V, Samarakoon U, et al
Differential SARS-CoV-2 Antibody Profiles after Allergic Reactions to mRNA COVID-19 Vaccine.
J Infect Dis. 2022 Mar 23. pii: 6553054. doi: 10.1093.
PubMed Abstract available

RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
PubMed Abstract available

LEWNARD JA, Bruxvoort KJ, Hong VX, Grant LR, et al
Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study.
J Infect Dis. 2022 Mar 22. pii: 6552253. doi: 10.1093.
PubMed Abstract available

LI X, Bilcke J, Vazquez Fernandez L, Bont L, et al
Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
J Infect Dis. 2022 Mar 16. pii: 6549175. doi: 10.1093.
PubMed Abstract available

ROHRIG A, Eyal N
The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
J Infect Dis. 2022;225:934-937.
PubMed Abstract available

ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Auphimai C, et al
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
J Infect Dis. 2022 Mar 10. pii: 6546425. doi: 10.1093.
PubMed Abstract available

HALL EW, Weng MK, Harris AM, Schillie S, et al
Assessing the cost-utility of universal hepatitis B vaccination among adults.
J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
PubMed Abstract available

SANTONJA I, Stiasny K, Essl A, Heinz FX, et al
Tick-borne encephalitis in vaccinated patients: a retrospective case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018.
J Infect Dis. 2022 Mar 2. pii: 6541329. doi: 10.1093.
PubMed Abstract available

February 2022

MORITZKY SA, Richards KA, Glover MA, Krammer F, et al
The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history.
J Infect Dis. 2022 Feb 24. pii: 6535476. doi: 10.1093.
PubMed Abstract available

BELSHE RB, Blevins TP, Yu Y, Nethington AE, et al
Neutralizing Antibody Kinetics and Immune Protection Against HSV-1 Genital Disease in Vaccinated Women.
J Infect Dis. 2022 Feb 24. pii: 6535411. doi: 10.1093.
PubMed Abstract available

LENTSCHER AJ, McAllister N, Griswold KA, Martin JL, et al
Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challenge.
J Infect Dis. 2022 Feb 23. pii: 6535121. doi: 10.1093.
PubMed Abstract available

BURNETT E, Parashar UD, Winn A, Tate JE, et al
Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021.
J Infect Dis. 2022 Feb 20. pii: 6532606. doi: 10.1093.
PubMed Abstract available

HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Grill DE, et al
Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination.
J Infect Dis. 2022 Feb 8. pii: 6524526. doi: 10.1093.
PubMed Abstract available

KIM N, Shin S, Minn D, Park S, et al
SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study.
J Infect Dis. 2022 Feb 1. pii: 6519374. doi: 10.1093.
PubMed Abstract available

RYAN KA, Schewe KE, Crowe J, Fotheringham SA, et al
Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.
J Infect Dis. 2022;225:404-412.
PubMed Abstract available

January 2022

SPENGLER JR, Kainulainen MH, Welch SR, Coleman-McCray JAD, et al
Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.
J Infect Dis. 2022 Jan 31. pii: 6517689. doi: 10.1093.
PubMed Abstract available

SKOWRONSKI DM, Setayeshgar S, Zou M, Prystajecky N, et al
Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada.
J Infect Dis. 2022 Jan 27. pii: 6515934. doi: 10.1093.
PubMed Abstract available

KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
PubMed Abstract available

GUAN M, Johannesen E, Tang CY, Hsu AL, et al
Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination.
J Infect Dis. 2022 Jan 13. pii: 6506263. doi: 10.1093.
PubMed Abstract available

KRISTENSEN JH, Hasselbalch RB, Pries-Heje M, Nielsen PB, et al
Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers.
J Infect Dis. 2022 Jan 5. pii: 6497955. doi: 10.1093.
PubMed Abstract available

CHU VT, Simon E, Lu X, Rockwell P, et al
Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019.
J Infect Dis. 2022;225:55-64.
PubMed Abstract available

December 2021

LEWIS LA, Gulati S, Zelek WM, Morgan BP, et al
Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement.
J Infect Dis. 2021 Dec 31. pii: 6491069. doi: 10.1093.
PubMed Abstract available

LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
PubMed Abstract available

BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
PubMed Abstract available

LIU J, Huang B, Li G, Chang X, et al
Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
PubMed Abstract available

ABARA WE, Gee J, Delorey M, Tun Y, et al
Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.
J Infect Dis. 2021 Dec 27. pii: 6484617. doi: 10.1093.
PubMed Abstract available

KIM SS, Naioti EA, Halasa NB, Stewart LS, et al
Vaccine Effectiveness against Influenza Hospitalization and Emergency Department Visits in Two A(H3N2) Dominant Influenza Seasons among Children <18 Years Old, New Vaccine Surveillance Network 2016-17 and 2017-18.
J Infect Dis. 2021 Dec 24. pii: 6482612. doi: 10.1093.
PubMed Abstract available

PHIJFFER EWEM, Bont LJ
Are we ready for maternal RSV vaccination?
J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
PubMed

LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
PubMed Abstract available

WALSH EE, Falsey AR, Scott DA, Gurtman A, et al
A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
J Infect Dis. 2021 Dec 21. pii: 6472747. doi: 10.1093.
PubMed Abstract available

FALSEY AR, Walsh EE, Scott DA, Gurtman A, et al
Phase 1/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
J Infect Dis. 2021 Dec 21. pii: 6472733. doi: 10.1093.
PubMed Abstract available

IYER AS, Harris JB
Correlates of Protection for Cholera.
J Infect Dis. 2021;224.
PubMed Abstract available

SAHA GK, Ganguly NK
Spread and Endemicity of Cholera in India: Factors Beyond the Numbers.
J Infect Dis. 2021;224.
PubMed Abstract available

CHAO DL
Mathematical Modeling of Endemic Cholera Transmission.
J Infect Dis. 2021;224.
PubMed Abstract available

SACK DA, Debes AK, Ateudjieu J, Bwire G, et al
Contrasting Epidemiology of Cholera in Bangladesh and Africa.
J Infect Dis. 2021;224.
PubMed Abstract available

FLECKENSTEIN JM, Sheikh A
Emerging Themes in the Molecular Pathogenesis of Enterotoxigenic Escherichia coli.
J Infect Dis. 2021;224.
PubMed Abstract available

BRUNHAM RC
Problems with Understanding Chlamydia trachomatis Immunology.
J Infect Dis. 2021 Dec 17. pii: 6469012. doi: 10.1093.
PubMed Abstract available

HASTIE A, Catteau G, Enemuo A, Mrkvan T, et al
Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
J Infect Dis. 2021;224:2025-2034.
PubMed Abstract available

HUI BB, Padeniya TN, Rebuli N, Gray RT, et al
A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men.
J Infect Dis. 2021 Dec 11. pii: 6459455. doi: 10.1093.
PubMed Abstract available

CHRISTENSEN H, Vickerman P
Gonococcal vaccines for controlling Neisseria gonorrhoeae in men who have sex with men: a promising game-changer.
J Infect Dis. 2021 Dec 11. pii: 6459454. doi: 10.1093.
PubMed

BROCKMAN MA, Mwimanzi F, Lapointe HR, Sang Y, et al
Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
J Infect Dis. 2021 Dec 9. pii: 6458430. doi: 10.1093.
PubMed Abstract available

NARANBHAI V, Garcia-Beltran WF, Chang CC, Mairena CB, et al
Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
J Infect Dis. 2021 Dec 9. pii: 6458467. doi: 10.1093.
PubMed Abstract available

November 2021

GILBOA M, Mandelboim M, Indenbaum V, Lustig Y, et al
Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
J Infect Dis. 2021 Nov 29. pii: 6446235. doi: 10.1093.
PubMed Abstract available

JOHNSON MJ, Liu C, Ghosh D, Lang N, et al
Cell-Mediated Immune Responses After Administration Of The Live Or The Recombinant Zoster Vaccine: Five-Year Persistence.
J Infect Dis. 2021 Nov 27. pii: 6444689. doi: 10.1093.
PubMed Abstract available

KIM JY, Lim SY, Park S, Kwon JS, et al
Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period.
J Infect Dis. 2021 Nov 25. pii: 6440288. doi: 10.1093.
PubMed Abstract available

RYCKMAN T, Karthikeyan AS, Kumar D, Cao Y, et al
Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
J Infect Dis. 2021;224.
PubMed Abstract available

KUMAR S, Ghosh RS, Iyer H, Ray A, et al
Typhoid in India: An Age-old Problem With an Existing Solution.
J Infect Dis. 2021;224.
PubMed Abstract available

CAO Y, Karthikeyan AS, Ramanujam K, Raju R, et al
Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data.
J Infect Dis. 2021;224.
PubMed Abstract available

SINHA B, Rongsen-Chandola T, Goyal N, Arya A, et al
Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier.
J Infect Dis. 2021;224.
PubMed Abstract available

MOHAN VR, Srinivasan M, Sinha B, Shrivastava A, et al
Geographically Weighted Regression Modeling of Spatial Clustering and Determinants of Focal Typhoid Fever Incidence.
J Infect Dis. 2021;224.
PubMed Abstract available

AMBROSINO D, Han HH, Hu B, Liang J, et al
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
J Infect Dis. 2021 Nov 19. pii: 6431853. doi: 10.1093.
PubMed Abstract available

FULDA ES, Fitch KV, Overton ET, Zanni MV, et al
COVID-19 Vaccination Rates in a Global HIV Cohort.
J Infect Dis. 2021 Nov 18. pii: 6431673. doi: 10.1093.
PubMed Abstract available

COLLIER AY, Yu J, Mcmahan K, Liu J, et al
COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.
J Infect Dis. 2021 Nov 18. pii: 6430790. doi: 10.1093.
PubMed Abstract available

ALAM MM, Ikram A, Mahmood N, Sharif S, et al
Antigenic structure of wild poliovirus type 1 strains endemic in Pakistan is highly conserved and completely neutralized by Sabin's Oral Polio Vaccine.
J Infect Dis. 2021 Nov 17. pii: 6430438. doi: 10.1093.
PubMed Abstract available

DUARTE G, Muresan P, Ward S, Laimon L, et al
Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.
J Infect Dis. 2021 Nov 16. pii: 6429421. doi: 10.1093.
PubMed Abstract available

BIERLE DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, et al
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
J Infect Dis. 2021 Nov 16. pii: 6429422. doi: 10.1093.
PubMed Abstract available

JOHNSON S, Martinez CI, Tedjakusuma SN, Peinovich N, et al
Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.
J Infect Dis. 2021 Nov 10. pii: 6425228. doi: 10.1093.
PubMed Abstract available

STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
PubMed Abstract available

FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
PubMed Abstract available

SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
Effectiveness of a third dose of BNT162b2 mRNA vaccine.
J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
PubMed Abstract available

October 2021

MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.
PubMed

CHAKRABORTY D, Kanungo S, Nandy RK, Deb AK, et al
Challenges for Programmatic Implementation of Oral Cholera Vaccine in India.
J Infect Dis. 2021 Oct 20. pii: 6404482. doi: 10.1093.
PubMed Abstract available

CALLEGARO A, Burny W, Herve C, Kim JH, et al
Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine.
J Infect Dis. 2021 Oct 18. pii: 6400271. doi: 10.1093.
PubMed Abstract available

WITHANAGE K, De Coster I, Cools N, Viviani S, et al
Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results.
J Infect Dis. 2021 Oct 15. pii: 6398205. doi: 10.1093.
PubMed Abstract available

PRENTICE S, Dockrell HM
BCG Specific and Nonspecific Effects: Different Questions, Similar Challenges.
J Infect Dis. 2021;224:1105-1108.
PubMed

WILLIAMS FB, Kader A, Colgate ER, Dickson DM, et al
Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh.
J Infect Dis. 2021;224:1147-1151.
PubMed Abstract available

DAGNEW AF, Klein NP, Herve C, Kalema G, et al
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged >/=65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
J Infect Dis. 2021;224:1139-1146.
PubMed Abstract available

PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
PubMed Abstract available

DILLER JR, Carter MH, Kanai Y, Sanchez SV, et al
Monoreassortant rotaviruses of multiple G types are differentially neutralized by sera from infants vaccinated with ROTARIX(R) and RotaTeq(R).
J Infect Dis. 2021 Oct 10. pii: 6386353. doi: 10.1093.
PubMed Abstract available

DODD RY, Notari EP, Brodsky JP, Foster GA, et al
Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.
J Infect Dis. 2021 Oct 9. pii: 6385747. doi: 10.1093.
PubMed Abstract available

LU Y, Jiao Y, Graham DJ, Wu Y, et al
Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.
J Infect Dis. 2021 Oct 7. pii: 6383455. doi: 10.1093.
PubMed Abstract available

GAST C, Bandyopadhyay AS, Saez-Llorens X, De Leon T, et al
Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials.
J Infect Dis. 2021 Oct 5. pii: 6381642. doi: 10.1093.
PubMed Abstract available

GERSHON AA, Gershon MD
Widespread use of varicella vaccine does not reduce immunity to zoster of others.
J Infect Dis. 2021 Oct 5. pii: 6381628. doi: 10.1093.
PubMed

CARRYN S, Cheuvart B, Povey M, Dagnew AF, et al
No consistent evidence of decreased exposure to varicella-zoster virus among older adults in countries with universal varicella vaccination.
J Infect Dis. 2021 Oct 5. pii: 6381619. doi: 10.1093.
PubMed Abstract available

September 2021

GLASS RI, Tate JE, Jiang B, Parashar U, et al
The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
J Infect Dis. 2021;224.
PubMed Abstract available

MARKOWITZ LE, Schiller JT
Human Papillomavirus Vaccines.
J Infect Dis. 2021;224.
PubMed Abstract available

GERSHON AA, Gershon MD, Shapiro ED
Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
J Infect Dis. 2021;224.
PubMed Abstract available

BECKER T, Elbahesh H, Reperant LA, Rimmelzwaan GF, et al
Influenza Vaccines: Successes and Continuing Challenges.
J Infect Dis. 2021;224.
PubMed Abstract available

PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
Hepatitis B Vaccines.
J Infect Dis. 2021;224.
PubMed Abstract available

RODGERS GL, Whitney CG, Klugman KP
Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe.
J Infect Dis. 2021;224.
PubMed Abstract available

HARBECKE R, Cohen JI, Oxman MN
Herpes Zoster Vaccines.
J Infect Dis. 2021;224.
PubMed Abstract available

GILSDORF JR
Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease.
J Infect Dis. 2021;224.
PubMed Abstract available

BREMAN JG
Smallpox.
J Infect Dis. 2021;224.
PubMed

MODLIN JF, Bandyopadhyay AS, Sutter R
Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
J Infect Dis. 2021;224.
PubMed Abstract available

PLOTKIN SA
Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
J Infect Dis. 2021;224.
PubMed Abstract available

DECKER MD, Edwards KM
Pertussis (Whooping Cough).
J Infect Dis. 2021;224.
PubMed Abstract available

GASTANADUY PA, Goodson JL, Panagiotakopoulos L, Rota PA, et al
Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination.
J Infect Dis. 2021;224.
PubMed Abstract available

KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
PubMed Abstract available

FERREIRA IATM, Kemp SA, Datir R, Saito A, et al
SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
J Infect Dis. 2021;224:989-994.
PubMed Abstract available

PROBERT WS, Glenn-Finer R, Espinosa A, Yen C, et al
Molecular Epidemiology of Measles in California, United States-2019.
J Infect Dis. 2021;224:1015-1023.
PubMed Abstract available

GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
PubMed Abstract available

VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
PubMed Abstract available

KIM SS, Chung JR, Belongia EA, McLean HQ, et al
mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
PubMed Abstract available

RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
PubMed Abstract available

DU PLESSIS M, de Gouveia L, Freitas C, Abera NA, et al
The Role of Molecular Testing in Pediatric Meningitis Surveillance in Southern and East African Countries, 2008-2017.
J Infect Dis. 2021;224.
PubMed Abstract available

August 2021

GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
Sex Differences in Influenza: The Challenge Study Experience.
J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
PubMed Abstract available

MAN I, Vanska S, Lehtinen M, Bogaards JA, et al
Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
J Infect Dis. 2021;224:481-491.
PubMed Abstract available

June 2021

WHITEHOUSE ER, Bonwitt J, Hughes CM, Lushima RS, et al
Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015.
J Infect Dis. 2021;223:1870-1878.
PubMed Abstract available

April 2021

WILHELM M, Kaur A, Wernli M, Hirsch HH, et al
BK Polyomavirus-Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination.
J Infect Dis. 2021;223:1410-1422.
PubMed Abstract available

EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
PubMed Abstract available

BLUMENFELD O, Hampe CS, Shulman LM, Chen R, et al
An Attenuation in the Incidence of Early Childhood Diabetes Correlates With Introduction of Rotavirus Vaccination in Israel.
J Infect Dis. 2021;223:1305-1307.
PubMed

SALEEM AF, Mach O, Yousafzai MT, Kazi Z, et al
One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.
J Infect Dis. 2021;223:1214-1221.
PubMed Abstract available

BEALL B, Walker H, Tran T, Li Z, et al
Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.
J Infect Dis. 2021;223:1241-1249.
PubMed Abstract available

RAMAN R, Brennan J, Ndi D, Sloan C, et al
Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines.
J Infect Dis. 2021;223:1250-1259.
PubMed Abstract available

WAGSTAFFE HR, Clutterbuck EA, Bockstal V, Stoop JN, et al
Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
J Infect Dis. 2021;223:1171-1182.
PubMed Abstract available

March 2021

JORDAN E, Lawrence SJ, Meyer TPH, Schmidt D, et al
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
J Infect Dis. 2021;223:1062-1072.
PubMed Abstract available

January 2021

DE PIJPER CA, Langedijk AC, Terryn S, Van Gucht S, et al
Long-term memory response after a single intramuscular rabies booster vaccination, 10-24 years after primary immunization.
J Infect Dis. 2021 Jan 27. pii: 6121364. doi: 10.1093.
PubMed Abstract available

September 2020

TOTA JE, Struyf F, Hildesheim A, Gonzalez P, et al
Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.
J Infect Dis. 2020 Sep 5. pii: 5901687. doi: 10.1093.
PubMed Abstract available

August 2020

SADOFF J, De Paepe E, Haazen W, Omoruyi E, et al
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
J Infect Dis. 2020 Aug 26. pii: 5897745. doi: 10.1093.
PubMed Abstract available

PANG Y, Wang Q, Lv M, Yu M, et al
Influenza vaccination protects against hospitalization outcomes among older patients with cardiovascular or respiratory diseases.
J Infect Dis. 2020 Aug 11. pii: 5890841. doi: 10.1093.
PubMed Abstract available

July 2020

CAMPBELL N, Verrall AJ, Donkor S, Sutherland JS, et al
BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia.
J Infect Dis. 2020 Jul 8. pii: 5868549. doi: 10.1093.
PubMed Abstract available

HU SY, Tsang SH, Chen F, Pan QJ, et al
Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women.
J Infect Dis. 2020 Jul 2. pii: 5866538. doi: 10.1093.
PubMed Abstract available

April 2020

SCHWENDINGER M, Thiry G, De Vos B, Leroux-Roels G, et al
A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
J Infect Dis. 2020 Apr 21. pii: 5821369. doi: 10.1093.
PubMed Abstract available

March 2020

KURTOVIC L, Atre T, Feng G, Wines BD, et al
Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial.
J Infect Dis. 2020 Mar 31. pii: 5814271. doi: 10.1093.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.